
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 20, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine MaleateTablets USP, 5 mg and 10 mg".
Filed with NSE ·

Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated March 20, 2023, titled "Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine MaleateTablets USP, 5 mg and 10 mg".
6ix hasn’t read this filing yet.
Glenmark Pharmaceuticals Limited on 6ix
Follow Glenmark Pharmaceuticals into a list and get an email when it puts out news.
Follow Glenmark Pharmaceuticals